FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBBLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody.
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) plus PomDex showed statistically significant and clinically meaningful progression-free survival compared to bortezomib plus PomDex; Consistent efficacy results observed for Blenrep combinations in two phase III head-to-head trials
FDA granted accelerated approval to belantamab mafodotin-blmf …
WEBBecause of the risks of ocular toxicity, belantamab mafodotin-blmf is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the BLENREP REMS.
Belantamab mafodotin - Wikipedia
WEBBelantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. [2] [5] [6] [3]
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
WEBFeb 5, 2024 · 36.6 months of median progression-free survival observed with Blenrep combination versus 13.4 months in daratumumab combination; Strong, clinically meaningful trend in overall survival favouring Blenrep combination …
WEBBLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
GSK publishes data from trial of multiple myeloma treatment
WEBFeb 6, 2024 · UK-based pharmaceutical company GSK has published interim results from the Phase III DREAMM-7 head-to-head clinical trial of Blenrep (belantamab mafodotin) regimen in relapsed or refractory multiple myeloma (r/r MM).
EMA Accepts MAA for Belantamab Mafodotin Combos in R/R
WEBJul 19, 2024 · The European Medicines Agency has accepted a marketing authorization application (MAA) seeking the approval of belantamab mafodotin (Blenrep) paired with bortezomib (Velcade) and dexamethasone...
WEBBLENREP is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). It works in unique ways to help fight multiple myeloma. BLENREP is the first and only ADC that targets BCMA, commonly seen on myeloma cells. It is possible that healthy cells may also be affected.
Drug Trials Snapshots: BLENREP | FDA
WEBApproval date: August 5, 2020. DRUG TRIALS SNAPSHOT SUMMARY: What is the drug for? BLENREP is a drug used to treat a form of blood cancer called multiple myeloma. It is to be used in patients...